Reprogrammed metabolism supports tumor growth and provides a potential source of therapeutic targets and disease biomarkers. Mass spectrometry-based metabolomics has emerged as a broadly informative technique for profiling metabolic features associated with specific oncogenotypes, disease progression, therapeutic liabilities and other clinically relevant aspects of tumor biology. In this review, we introduce the applications of metabolomics to study deregulated metabolism and metabolic vulnerabilities in cancer. We provide examples of studies that used metabolomics to discover novel metabolic regulatory mechanisms, including processes that link metabolic alterations with gene expression, protein function, and other aspects of systems biology. Finally, we discuss emerging applications of metabolomics for in vivo isotope tracing and metabolite imaging, both of which hold promise to advance our understanding of the role of metabolic reprogramming in cancer.
A C C E P T E D M A N U S C R I P T

Introduction
Metabolism supports various aspects of normal cell biology, including breakdown of fuels such as carbohydrates, fats, and amino acids to generate energy and biosynthetic precursors for growth [1] . These fundamental features of cellular metabolism are reprogrammed in cancer cells to support their pathological levels of growth and proliferation. Metabolic reprogramming in malignant cells is likely the result of the multifactorial effects of genomic alterations (i.e. mutations of oncogenes and tumor suppressors), the tumor microenvironment (which imposes metabolic stress caused by compromised nutrients and oxygen availability), and other influences [1] [2] [3] .
We need to understand the complete breadth of metabolic abnormalities in cancer because some metabolic changes provide opportunities to develop novel therapeutic targets and predictive biomarkers.
Generations of studies reaching back to the 1920s have analyzed metabolic alterations in cancer, with enhanced glucose utilization being the most frequently and broadly observed. The clinical relevance of metabolic reprogramming in tumors is supported by routine use of the glucose analog fluorodeoxyglucose as a radiolabeled tracer for positron emission tomography-based imaging (FDG-PET) [4] . As newer technologies have become available to characterize tumor metabolism more broadly and specifically than ever before, many other examples of potentially clinicallyactionable metabolic perturbations have become apparent, indicating that the propensity for enhanced glucose uptake is merely the tip of the iceberg [5] .
Understanding cancer metabolism requires systematic application of analytical techniques to assess metabolite levels in biological samples from healthy and diseased
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A N U S C R I P T 4 tissues. Metabolomics has emerged as the most powerful platform to recognize metabolic anomalies in urine, serum or tissue samples [6, 7] . In general, metabolomics techniques provide semi-quantitative or quantitative information about the steady-state abundance of intermediates from many metabolic pathways simultaneously, providing the user with an overview of the metabolic network and its perturbation in disease [8, 9] .
This review discusses metabolomics methods and presents examples where metabolomics has been used to uncover new concepts in cancer biology or to identify novel targets for diagnostic imaging and therapy.
Metabolomics: An informative platform to study cancer metabolism
Metabolomics requires analytical techniques such as nuclear magnetic resonance spectroscopy (NMR) and mass-spectrometry (MS) to measure metabolites in biological samples. NMR detects the magnetic spin of molecular nuclei under a defined magnetic frequency and is effective at identifying metabolites from complex mixtures, quantifying metabolite abundance, and assessing the position of specific nuclei (e.g. 13 C) within a metabolite of interest, all with excellent reproducibility [10, 11] . NMR has the advantage of providing non-destructive analysis and the potential for in vivo metabolite detection in humans. Proton magnetic resonance spectroscopy (MRS)
provides non-invasive detection of D-2-hydroxyglutarate (D-2HG) in gliomas with
IDH1/2 mutations, and confirmed the previously observed profile of elevated choline and downregulated creatine and N-acetyl aspartate in gliomas compared to normal human brain [12, 13] . Similarly, 13 C magnetic resonance spectroscopy (
C MRS)
analysis of healthy individuals infused with [U- 13 C] glucose identified glucose flux into the TCA cycle via pyruvate dehydrogenase in healthy brain [14] . Limitations of NMR for
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MS-based techniques rely on the mass/charge (m/z) ratio of a metabolite or its fragments. These techniques have extremely high sensitivity, with commercial instruments enabling the detection of metabolites in tiny samples of a few thousand cells or less and achieving femtomolar sensitivity [11, [15] [16] [17] . MS analysis can require parallel extraction procedures to recover polar, non-polar and volatile compounds for analysis, and extensive processing can lead to sample disintegration with loss of the most labile compounds. However, rapid advancements in mass spectrometry hardware, ionization techniques, and data-analysis software have steadily increased the scope of MS-based metabolomics experiments in both targeted and untargeted applications, making MS the most prominent technology in modern metabolomics [11, 17] .
A common application of metabolomics has been to discover biomarkers for diagnosis or to predict therapeutic sensitivity and prognosis [18] . For example, relatively early metabolomics experiments in breast cancer identified positive associations between levels of choline, glycine, and lactate, and histopathological grade and tumor size [19, 20] . Similar work in tissue samples from ovarian [21] , prostate [22, 23] , brain [24, 25] , and kidney [26, 27] cancers and breath samples from lung cancer patients [28] identified metabolic perturbations within tumor grades and sizes. Specifically, choline and related metabolites were elevated in prostate and pediatric brain tumors, while lipids were elevated in kidney tumors. These studies employed various forms of statistical modelling to determine metabolic signatures that differentiated tumor from noncancerous tissues, and distinguished tumor stages and grades from each other.
Metabolic disturbances associated with genomic alterations in metabolic enzymes
Many early metabolomic studies identified metabolic differences between tumors and non-cancerous tissues, but lacked understanding of the molecular basis for these differences. More recently, the simultaneous implementation of molecular biology techniques and other integrative strategies together with metabolomics has played an essential role in deciphering the molecular underpinnings of metabolic reprogramming in cancer. We now appreciate that genomic or gene expression alterations in key enzymes of metabolic pathways support oncogenic transformation and/or enable tumor growth and progression. A current challenge is to understand how these changes contribute to tumor biology and which might be amenable to therapeutic targeting. In a few important cases discussed in this section, mutations in metabolic enzymes result in the accumulation of metabolites that directly contribute to malignant transformation.
These metabolites are commonly referred to as oncometabolites, and although they account for a small subset of reprogrammed metabolism, they are highly instructive because they provide insight into mechanisms of tumorigenesis and the impact of metabolic perturbation on tissue function.
A. Oncometabolites generated by gain of neomorphic enzyme activity
Isocitrate-dehydrogenases (IDH1, IDH2 and IDH3) catalyze the NAD + /NADP + -dependent decarboxylation of isocitrate to α-ketoglutarate (α-KG) [29] . While IDH1 is localized to cytosol and peroxisomes, IDH2 and IDH3 are mitochondrial enzymes.
About 10 years ago, IDH1 and IDH2 mutations were identified in patients with low-and intermediate-grade gliomas and in glioblastomas arising from these initially less
aggressive lesions [30, 31] . These mutations result in suppression of the canonical NADP + -dependent oxidative decarboxylation of α-KG. However, the mutations are monoallelic and essentially always located in the same residues in the IDH1/IDH2 active site, suggesting a gain-of-function mechanism relevant to tumor initiation. Metabolomics identified millimolar levels of D-2-hydroxyglutarate (D-2HG), a metabolite normally present at trace levels, in gliomas and cell lines expressing mutant IDH1 [32] . The R132 mutation in IDH1 confers a neomorphic activity resulting in NADPH-dependent generation of D-2HG from -KG [32] (Figure 1 ). Soon after this observation, mutations in IDH1 and IDH2 were identified in acute myeloid leukemia (AML) [33] , thyroid cancer [34] , and in other tumor types [35] . Invariably, R132 mutations in IDH1 result in D-2HG accumulation, suggesting a critical role for D-2HG in driving tumorigenesis.
Orthogonal studies demonstrated that D-2HG functionally impairs α-KG dependent dioxygenases, such as histone and DNA demethylases and prolyl hydroxylases [35] [36] [37] ( Figure 1 ). Small-molecules inhibiting mutant IDH1/2 were demonstrated to suppress D-2HG production, reduce tumor growth and/or induce differentiation of experimental models of glioma [38] and leukemia [39, 40] , indicating the therapeutic potential of targeting these mutations. These remarkable discoveries ultimately led to the US Food and Drug Administration (FDA) approval of the mutant IDH2 inhibitor enasidenib (IDHIFA, Celgene Corp.) for the treatment of AML patients [41] , with ongoing clinical trials in other forms of IDH-mutant cancer.
B. Oncometabolites generated by loss of enzyme activity
Mutations in the TCA cycle enzymes succinate dehydrogenase (SDH) [42, 43] and fumarate hydratase (FH) [44] lead to familial cancer syndromes such as paraganglioma,
pheochromocytoma and papillary renal cell carcinoma, indicating that these enzymes function as tumor suppressors [45] . Unlike IDH mutations, FH and SDH mutations result in the loss of enzymatic function, usually through the inheritance of one germline lossof-function mutation followed by loss of the second allele in the tumor. This results in the accumulation of the substrates fumarate and succinate, both of which inhibit α-KG dependent dioxygenases (Figure 1 values, fumarate and succinate inhibit α-KG dependent prolyl hydroxylases [46, 47] , TET enzyme-regulated hydroxylation of methyl-cytosine [48] including in the promoters of HIF-regulated genes [49] , and histone demethylases [48] , conferring genome and proteome modifications that support oncogenic transformation. Studies suggest that both metabolites can modulate the epithelial-mesenchymal transition (EMT). The fumarate driven EMT gene-signature is independent of HIF signaling but requires inhibition of TET enzyme-dependent demethylation of microRNA clusters that negatively regulate metastasis in papillary and renal cell carcinoma [50] . In paraganglioma and kidney cells lacking functional SDH, succinate inhibits α-KG dependent dioxygenases, resulting in histone hypermethylation and acquisition of EMT-like migratory phenotypes [50, 51] . Fumarate also covalently modifies reactive sulfhydryl groups on cysteine residues through a process called succination. Elevated levels of fumarate result in the conversion of glutathione (GSH) to succinated GSH, reducing NADPH abundance and enhancing ROS and HIF1α activation [52] . Fumarate also succinates cysteine residues of Kelch Like ECH Associated Protein 1 (KEAP1), abrogating its
ability to repress nuclear factor erythroid 2-related factor 2 (NRF2), which regulates expression of antioxidant genes and promotes tumorigenesis [53] .
Metabolomics identifies subtype-selective therapeutic liabilities in cancer
Metabolomics can be used to reveal metabolic differences among different tumor subclasses from the same anatomic location. Some of these differences reflect the cellautonomous effects of specific oncogenotypes, while others reflect the complex effects of evolving tumor biology during cancer progression. Regardless of the cause, such metabolic changes might present new opportunities for diagnostic imaging or therapy. In this section, we discuss applications of metabolomics to identify metabolic features that stratify tumors into molecular or biological subclasses.
A. Metabolic abnormalities governed by cancer genotypes
In many non-transformed epithelial and hematopoietic cells, nutrient uptake is tightly regulated by growth factor signaling, allowing cells to engage growth-promoting metabolic pathways precisely when they receive exogenous signals to proliferate. The PI3K-AKT-mTOR signaling pathway is a major effector of growth factors and induces numerous bioenergetic and biosynthetic pathways through post-translational protein modifications, activating transcriptional networks, and other mechanisms [54] [55] [56] [57] [58] . This pathway frequently becomes constitutively activated in cancer due to mutations/amplifications of key regulatory subunits and/or deletion of tumor suppressors. For example, phosphatase and tensin homolog (PTEN), the key negative regulator of PI3K, is the most frequently deleted tumor suppressor [59] [60] [61] . PTEN transgenic mice with additional genomic copies of PTEN demonstrate increased energy
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A C C E P T E D M A N U S C R I P T 10 expenditure and reduced body mass [62, 63] , and embryonic fibroblasts from these mice display elevated oxidative phosphorylation and reduced glycolysis as a result of repressed PI3K/AKT signaling [63] . to maintain glucose flux through the HBP and the non-oxidative PPP. Oncogenic KRAS also diverts glutamine-derived aspartate to malate in the cytoplasm through increased expression of glutamic-oxaloacetic transaminase 1 (GOT1) in PDAC cells [69] .
Subsequently, malate-derived oxaloacetate generates pyruvate and NADPH via malic enzyme, and the NADPH is used to maintain a reduced GSH pool for ROS
homeostasis [69] . Such rewiring of glutamine metabolism confers independence of the oxidative pentose phosphate pathway for NADPH production. KRAS-mutant colorectal cancer (CRC) cells convert glutamine-derived aspartate to asparagine and show sensitivity to inhibitors of asparagine synthetase (ASNS) [70] . Interestingly, KRASmutant CRC cells maintain asparagine levels through PI3K-AKT-mTOR pathway mediated ASNS expression [70] . Thus, oncogenic KRAS has pleiotropic metabolic effects that result in different metabolic liabilities in different cancer types.
BRAF, another member of the RAS family of oncogenes, is also frequently mutated in cancer. Numerous studies have illustrated the impact of the BRAF V600E on metabolic phenotypes. Genome wide shRNA screening identified 3-hydroxy-3-methylglutaryl-CoA lyase (HMGCL) as a metabolic vulnerability associated with BRAF V600E melanoma [71] . HMGCL generates the ketone body acetoacetate, which physically binds to mutant BRAF protein to stabilize its interaction with MitogenActivated Protein Kinase Kinase 1 (MEK1), thus potentiating BRAF-dependent signals [71] . These BRAF and MAPK dependent melanomas show reduced mitochondrial metabolism and decreased expression of peroxisome proliferatoractivated receptor gamma coactivator 1-alpha (PCG1α) [72] . In patient-derived melanoma xenografts, the BRAF V600E genotype is associated with abundant glycolytic metabolites and enhanced activity of the glycolytic pathway in vivo [73] .
MYC family members are the most frequently amplified or otherwise activated oncogenic transcription factors across human tumor types [74] . MYC stimulates glucose and glutamine metabolism by regulating expression of genes related to these pathways, including lactate dehydrogenase-A (LDHA) [75] , glucose transporter (GLUT1) [76] and
glutaminase (GLS1) [77] . Metabolomic studies have broadened our understanding of the diverse functions of MYC in regulating many other metabolic pathways in cancer. In triple negative breast cancer, MYC regulates metabolites and genes involved in fatty acid oxidation, resulting in enhanced levels of acylcarnitine intermediates and rendering tumors sensitive to inhibitors of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme in this pathway [78] . MYC also regulates 2-hydroxyglutarate (2-HG)-dependent DNA hypermethylation in tripe negative breast cancer [79] . Global metabolic profiling of MYC-driven colorectal tumors identified significant metabolic dysregulation at the advanced adenoma stage [80] . In this model, MYC regulates genes involved in purine/pyrimidine metabolism, glycolysis, and the pentose phosphate pathway as well as fatty acid synthesis. However, in contrast to its role in triple negative breast cancer, MYC overexpression downregulates fatty acid oxidation genes in colorectal cancer [80] , further emphasizing that the metabolic effects of oncogene activation may manifest differently in different tumors.
B. Metabolic dysregulation associated with tumor progression or aggressiveness
Cellular metabolism is thought to evolve during cancer progression, and several studies demonstrate how metabolomics can be used to nominate evolving metabolic features as biomarkers or therapeutic targets. To identify non-invasive biomarkers for diagnosis and prognosis of prostate cancer, Sreekumar et. al used metabolomics to assess global metabolic alterations in urine, serum, and prostate cancer tissues [81] .
Sarcosine, a naturally-occurring N-methylated form of glycine, was progressively elevated in localized and metastatic tissues (Figure 3 ) and urine samples. Treating benign prostate epithelial cells with sarcosine or silencing the sarcosine-degrading
enzyme sarcosine dehydrogenase (SARDH) enhanced invasive properties, while knockdown of the sarcosine-synthesizing enzyme glycine N-methyltransferase (GNMT) reduced invasion of prostate cancer cells [81] . Several [82, 83] but not all [84, 85] subsequent studies have validated elevated sarcosine level in tissues and urine samples from prostate cancer patients.
The metabolomics data generated by Sreekumar et al [81] have subsequently been used to identify other metabolic networks contributing to prostate cancer progression. We observed that inhibition of the hexosamine biosynthesis pathway (HBP) promotes castration-resistant prostate cancer (CRPC) [86] (Figure 3) . While the HBP is essential for localized prostate cancer growth [86] , its downregulation promotes CRPC, making the HBP an example of metabolic rewiring associated with cancer progression. Additionally, metabolomics of androgen-dependent and castrationresistant prostate cancer cell lines identified correlations between UDPglucuronosyltransferase expression and disease progression [87] . In CRPC, constitutive activation of the androgen receptor (AR) is associated with resistance to 2 nd generation anti-androgens. Interestingly, AR-V7, a spliced form of full-length AR that is expressed in anti-androgen enzalutamide and abiraterone-acetate resistant CRPC patients [88] , was found to decrease the abundance of citrate [89] and increase utilization of glutamine-derived reductive carboxylation of α-KG in prostate cancer LNCaP cells expressing AR-V7 [89] . Similarly, steroid receptor coactivator-2 (SRC-2), a nuclear receptor interacting protein with histone acetyltransferase activity, is elevated in metastatic prostate cancer and regulates glutamine-derived reductive carboxylation of α-KG in CRPC and metastatic cell lines [90] . impacting subcutaneous tumor growth [73] . These findings indicate that metabolomics can be sensitive enough to detect changes in the epigenetic state and can identify activities that enable metastasis in vivo.
Another study using these same melanoma PDXs focused on metabolic differences between tumor cells at the subcutaneous site, in the circulation and in metastases in visceral organs [102] . Tumor cells in the circulation and in visceral metastases had evidence of oxidative stress and enhanced activity of the folate pathway to generate NADPH for ROS homeostasis, indicating that ROS imposed a bottleneck on metastasis in these models (Figure 3) . Treating tumor-bearing mice with the antioxidant N-acetyl cysteine (NAC) increased the number of tumor cells in circulation and enhanced metastatic burden, whereas imposing modest oxidative stress with low-dose methotrexate suppressed metastasis [102] . Additional mechanistic studies in cell culture further support a role for ROS mitigation in anchorageindependent survival and growth, key determinants of the metastatic cascade. Loss of NADPH production from the pentose phosphate pathway was observed to limit the survival of non-transformed cells during loss of anchorage, and this could be overcome
A C C E P T E D M A N U S C R I P T 18
by expressing an oncogene [103] . In cancer cells, loss of attachment to a 2-dimensional matrix was associated with enhanced levels of mitochondrial ROS which limited the growth of detached tumor spheroids [104] . In this system, mitigating mitochondrial ROS required transfer of NADPH from the pentose phosphate pathway in the cytosol into the mitochondria. The transfer mechanism involved NADPH-dependent reductive carboxylation of cytosolic α-KG by IDH1, followed by entry of the resulting isocitrate/citrate into the mitochondria where it supplied IDH2-depenent NADPH production [104] . Altogether, these studies demonstrate how metabolism is rewired to mitigate elevated ROS associated with disease progression and metastasis. TAMs demonstrate elevated glycolysis and pentose phosphate pathway activity [109] .
C. Metabolic cross-talk between cancer cells and immune cells
Several excellent reviews describe metabolic adaptations in immune cells in various diseases, including cancer [106, 110] .
A C C E P T E D M A N U S C R I P T 19
With the approval of anti-PD1 and anti-PDL1 immunotherapy such as nivolumab for advanced cancer, there is an emerging interest in deciphering metabolic alterations associated with immunotherapy. Giannakis et al. used LC/MS-based metabolomics to identify changes in the serum of melanoma and RCC patients treated with nivolumab [111] . Melanoma patients that responded to therapy showed increased levels of kynurenine [111] , an intermediate of tryptophan degradation with inflammatory and immunomodulatory properties [112] . In RCC, nivolumab non-responders showed increased adenosine and poor progression free survival [111] . androgen [114] . Subsequently, metabolomics analysis confirmed alterations in these pathways in androgen treated cells [114] . Hakimi et al used pathway-based enrichment analysis to identify alterations in several metabolic pathways in ccRCC, but also demonstrated lack of uniform concordance between metabolite levels and corresponding enzyme-coding gene expression in ccRCC [96] . This observation likely reflects the myriad regulatory mechanisms in addition to gene expression that regulate
pathway activity, and argues that advanced applications of systems biology are needed to improve our understanding of interactions between genes, proteins, and metabolites.
In recent years, novel pathway and network-based integrative approaches have been developed to combine data from multi-omics studies, especially metabolomics and transcriptomics. We used the Oncomine concept map (OCM) [87] and network based gene set analysis (NetGSA) [86] to combine data from transcriptomics and metabolomics in prostate cancer. OCM is a pathway-based analysis platform that requires a list of differential enzyme-coding genes or metabolites to test the enrichment of associated biological processes, also termed as molecular concepts, using Fisher's exact test [115] . Advanced network-centric framework utilizes information on genegene/protein-protein interactions and reactome based information with associated stoichiometry. We applied network-based integrative analysis in prostate cancer to first derive pathway scores from gene-expression data using gene set analysis (GSA) and from metabolomics data using network-based gene set analysis (NetGSA) [86] . Unlike gene-set enrichment analysis, NetGSA utilizes reactome-based metabolite-interactions and stochiometric information, which increases the power of this statistical model [116] .
Finally, the pathway scores were combined using a bootstrap resampling procedure to nominate significant enrichment of the HBP and pathways of riboflavin, biotin, cysteine, and valine-isoleucine metabolism in prostate cancer [86] .
Others have applied similar network-based approaches. Zhang et al. used weighted co-expression network analysis (WGCNA) to identify highly interconnected nodes of metabolic pathways associated with fatty acid metabolism in pancreatic ductal adenocarcinoma (PDAC) [117] . First, the authors generated a matrix of pairwise
Pearson correlation coefficients for each metabolite in all tumors, then defined an adjacent matrix using a power function. The resulted weighted network was assessed using WGCNA to enrich for highly interconnected modules based on network topology.
Next, genes corresponding to top altered metabolites were analyzed in tumor samples to determine their association with pathways derived using WGCNA [117] .
Several other studies have used various forms of integrative approaches to classify novel interactions between metabolomics and other dimensions of systems biology. Su et al. interrogated metabolomics and gene-expression from the NCI-60 cell lines to study relationships between metabolite and transcripts [118] . They observed that the metabolome can distinguish cancer subtypes and that metabolite levels correlate well with gene expression under strong correlation models [118] . Yang et al. performed a comprehensive assessment of metabolomics and gene expression from cervical cancer patients and identified potential diagnostic biomarkers [119] . Using a similar approach that also incorporated pathway over-representation analysis, Fahrmann et al. combined metabolomics and proteomics to identify altered nicotinamide and polyamine metabolism in lung adenocarcinoma [120] . Using parameters of biochemical reactions, enzyme expression and metabolite levels, Auslander et al. combined gene-expression and metabolomics data from breast cancer patients to identify significant metabolitegene correlations in both malignant and non-malignant tissues, with more abundant correlations in cancer tissues [121] . Interestingly, the authors developed a support vector machine model that predicted metabolite levels based on gene-expression data and performed quite well in breast cancer and hepatocellular carcinoma [121] . Altogether,
these studies highlight the potential of systems-based approaches, and many online tools are available to perform such integrative analyses [122] [123] [124] .
A current challenge in integrative analysis is to identify common metabolomic alterations across multiple cancer types; such alterations could shed light on common mechanisms of transformation and might uncover opportunities for generalizable therapies. These analyses have proven difficult in part because of the lack of standard methods to combine datasets generated in different tumor types, from different institutions, and/or incorporating different metabolomics methods. These hurdles were highlighted in a meta-analysis of clinical metabolomics studies from diverse tumor types [125] . The authors combined data using binary vote-counting methods, which uses a voting function of +1 for elevation and -1 for downregulation for each metabolite across all cohorts to derive a composite voting score. This approach identified high levels of lactate and glutamic acid in cancer tissues from multiple cohorts. It also noted the dearth of complete and raw datasets in many of the published studies, perhaps because of the lack of universally-accepted metabolomics practices, limiting the scope of meta-analyses [125] . Hopefully the dissemination of standard metabolomics protocols via the Metabolomics Workbench [126] and other efforts will improve the implementation of integrative approaches.
A related challenge in integrative analysis is the incomplete coverage of the metabolome provided by different methods. To address this challenge, multiple groups are developing improved extraction and chromatography techniques and enhancing mass-spectrometry sensitivity to increase the breadth of metabolites that can be quantified in a single experiment [127, 128] . In recent years, techniques of untargeted
LC/MS metabolomics have been successfully applied to improve metabolome coverage from biological samples. Novel bioinformatics software, such as XCMS [129] [130] [131] , can perform non-linear integration of raw spectral peaks and identify thousands of novel metabolic features across multiple biological samples. Thus, the next few years should bring improved implementation of targeted and untargeted metabolomics techniques to map global metabolic changes in cancer and other diseases.
Advanced applications of metabolomics
In vivo isotope tracing and metabolite imaging have emerged as advanced techniques to assess metabolism. In this section, we briefly discuss applications of these techniques to generate insights about cancer metabolism in intact tissues.
A. Tracing of isotope labeled metabolites
Unlike metabolomics, isotope tracing (i.e. monitoring distribution of an isotope label originating on a nutrient of interest) provides information about metabolic pathway activity. Isotope tracing has been used extensively to characterize altered metabolic fluxes arising from mutations in tumor suppressors and oncogenes, or resulting from various metabolic stressors in cancer cells. The reader is referred to several reviews discussing principles and experimental techniques in isotope tracing [132] [133] [134] . Here we discuss a few original papers that helped shape current concepts in cancer metabolism.
Isotope tracing with display substantial inter-and intratumor metabolic heterogeneity [144] ; and c) exhibit nutrient preferences associated with the degree of tissue perfusion, with the bestperfused areas complementing glucose oxidation with oxidation of additional fuels [144] .
An interesting outcome of in vivo human infusion studies has been to identify some of
these alternative fuels. Tumors in the human brain were observed to use the short chain fatty acid acetate as a carbon source for the TCA cycle [145] . In lung tumors in both humans and mice, lactate from the circulation provided carbon for the TCA cycle, a surprising finding given the long-standing expectation that lactate is primarily a waste product in cancer [146, 147] .
Conventional methods in isotope tracing usually capitalize on a priori knowledge of which downstream metabolites should carry label from the precursor. A number of newer approaches allow the user to perform unbiased detection of isotope-labeled molecules, providing the opportunity to detect truly novel pathways. These techniques, which include nontargeted tracer fate detection (NTFD) [148] and X13CMS [149] , require extensive computation and statistical modelling and pose challenges in data interpretation [150] . Nevertheless, a recent study applied few of these concepts in a targeted analysis in mice fed with liquid diet containing [U- hours. This study demonstrated significant enrichment of 13 C in wide range of metabolic pathways, including HBP, PPP, lipids, as well as in proteins [151] , documenting the feasibility of global metabolite labeling in vivo.
B. Metabolite Imaging
The tumor metabolomics and isotope tracing experiments described above [155] . MALDI-MSI and the related technique desorption electrospray ionization MSI (DESI-MSI) have been used to assess regional metabolite distribution in tissues from human and mouse models of renal cell carcinoma [156, 157] , prostate cancer [158] , gastric cancer [159] , and sarcoma [160] , in some cases identifying specific metabolic effects of oncogenic drivers in the tumor tissue. MSI approaches have also been used to detect conversion of precursor to product molecules, thereby providing proof of principle that the technique has the capability to monitor some metabolic activities [161] . Altogether, these studies illustrate the emerging role of MSI in studying
cancer metabolism and understanding the role of the native microenvironment in dictating metabolic phenotypes in vivo [162] [163] [164] .
Future Perspective
Recent years have seen the expanded use of metabolomics to study cancer.
These studies have been propelled by rapid improvements both in our understanding of the molecular basis of metabolic reprogramming, and in the analytical systems with which cancer metabolism can be studied. The availability of isotope labeling methods, metabolite imaging, and tools to integrate metabolic data with genomics, transcriptomics, and proteomics have the potential to accelerate research in cancer metabolism even further, particularly in the context of intact tumors in mice and humans.
We anticipate further advancements in global metabolite profiling, hopefully with an increasing emphasis on methodological consistency to facilitate durable data sharing and reproducibility across centers.
Figure Legends Oncometabolites inhibit α-KG-dependent dioxygenases. α-KG is required for the function of a family of dioxygenase enzymes including histone demethylases, which remove methyl groups from lysine residues in histone proteins; 5-methylcytosine hydroxylases, which initiate demethylation of cytosine bases; and prolyl hydroxylases, which hydroxylate proline residues in proteins such as the α subunits of hypoxia inducible factors (HIFs). These dioxygenases can be inhibited by high levels of other dicarboxylic acids, which compete with α-KG. Dicarboxylic acids demonstrated to inhibit dioxygenases include D-HG (a product of mutant IDH1/2) and fumarate and succinate, which accumulate due to loss-of-function mutations in FH and SDH, respectively. Non-small cell lung cancer (NSCLC) with concomitant mutations in KRAS and LKB1 use an unusual form of pyrimidine biosynthesis initiated by carbamoylphosphate synthetase-1 (CPS1). NSCLC with mutations in KRAS and p53 display glucosedependent glutathione (GSH) biosynthesis. b. KRAS-mutant pancreatic ductal adenocarcinoma (PDAC) requires MAPK signaling to regulate glucose flux into the hexosamine biosynthesis pathway (HBP) and non-oxidative pentose phosphate pathway (Non-Oxidative PPP). These pathways contribute to protein glycosylation and nucleic acid synthesis, respectively.
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A N U S C R I P T Figure 3 . Metabolic rewiring during cancer progression. In prostate cancer, elevated sarcosine is associated with metastasis while downregulation of the hexosamine biosynthesis pathway (HBP) is associated with castration-resistance. In clear cell renal cell carcinoma (ccRCC), elevated glutathione (GSH), dipeptide metabolites, and metabolites from the 1-carbon/folate pathway are associated with metastasis while α-hydroxybutyrate is associated with disease recurrence. Decreased levels of lipids and citrate are observed as lower-grade tumors progress to high-grade ccRCC. In melanoma, trimethyllysine, dimethylarginine, and induction of the 1-carbon/folate pathway are associated with metastasis, while elevated ROS is associated with inhibition of metastasis. Systems biology provides systematic techniques to interrogate the complex interaction of genes and proteins with metabolites. Broadly, high throughput data generated from multiple compartments can be integrated with metabolomics using three different approaches. Concordance analysis uses direct information from the transcript/protein expression of enzymes and levels of product and substrate of the reaction. As an example, high levels of glucose and glucose 6-phosphate (Glucose-6-P) correlate with elevated hexokinase 1 (HK1) expression. Pathway based enrichment analysis uses statistical tests, such as Fisher's exact test, to determine the likelihood of observing alterations in groups of metabolites/genes associated with specific metabolic pathways. In the corresponding figure, node size represents the number of metabolites in a pathway, and enrichment score represents directionality of enriched pathways based on composite score of differential metabolites. Network based integration uses interaction information about genes, proteins and metabolites as well as stoichiometry information of reactomes to design networks to test enrichment of metabolic pathways using several mathematical models. In the figure, node size corresponds to number of metabolites in a pathway, and interaction between pathways and directionality of flux are represented by arrows of varying width. Isotope tracing studies in lung cancer patients have established that glucose and lactate are oxidized in the TCA cycle in vivo. These studies have also revealed the activity of both pyruvate dehydrogenase and pyruvate carboxylase (PDH and PC) in vivo. In the illustration, PDH activity results in TCA cycle intermediates with two 13 C nuclei and PC activity results in TCA cycle intermediates with three 13 C nuclei. Metabolite imaging (right) using matrix assisted laser desorption/ionization (MALDI) provides temporal and spatial resolution of metabolite abundance to observe metabolic differences across tissue sections. Metabolite imaging has been used in murine glioma models to assess changes in glycolytic and TCA cycle intermediates. 
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